MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
NCT07863466
Summary
Chronic myeloproliferative neoplasms (MPNs) are hematologic disorders of the myeloid lineage characterized by clonal proliferation of hematopoietic stem cells, high risk of thrombotic-hemorrhagic complications, and transformation into secondary acute myeloid leukemia. MPNs include: myelofibrosis, polycythemia vera, and essential thrombocythemia. The low incidence, comparable to that of rare diseases, induces the in-depth study of patients and thus the need to develop a project with databases to collect clinical, biological, and therapeutic information.
Eligibility
Inclusion Criteria: * Patients 16 years of age and older * Patients diagnosed with polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis (Arber et al, Blood 2022 or earlier but reclassified classifications) Exclusion Criteria: * Patients with diagnosis other than polycythemia vera, essential thrombocythemia, prefibrotic and overt primary myelofibrosis, secondary myelofibrosis * Follow up of less than 6 months
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07863466